Anixa Biosciences Inc
NASDAQ:ANIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Anixa Biosciences Inc
Accrued Liabilities
Anixa Biosciences Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Anixa Biosciences Inc
NASDAQ:ANIX
|
Accrued Liabilities
$1.1m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
9%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
$8.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accrued Liabilities
$2.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
19%
|
|
Anixa Biosciences Inc
Glance View
Anixa Biosciences, Inc. is a biotechnology company, which engages in developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. The company is headquartered in San Jose, California and currently employs 4 full-time employees. The firm is developing therapies and vaccines that are focused on oncology and infectious disease. The firm is developing chimeric endocrine receptor T-cell technology, a chimeric antigen receptor T-cell (CAR-T) technology focused on treating ovarian cancer, and anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. The company is also developing vaccine against triple negative breast cancer (TNBC), the lethal form of breast cancer, and a vaccine against ovarian cancer. Its CAR-T technology can be used as a treatment against multiple solid tumor types. The Company’s segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, Cancer Diagnostics activities, and Patent Licensing activities. Its subsidiary Certainty Therapeutics, Inc. (Certainty), is developing immuno-therapy drugs against cancer.
See Also
What is Anixa Biosciences Inc's Accrued Liabilities?
Accrued Liabilities
1.1m
USD
Based on the financial report for Jan 31, 2026, Anixa Biosciences Inc's Accrued Liabilities amounts to 1.1m USD.
What is Anixa Biosciences Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
9%
Over the last year, the Accrued Liabilities growth was -22%. The average annual Accrued Liabilities growth rates for Anixa Biosciences Inc have been -1% over the past three years , 1% over the past five years , and 9% over the past ten years .
